90-Second Read: Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

These antiviral molecules target a highly conserved region of the viral replication enzyme, specifically the L-protein of Andes Hantavirus, which is essential for viral replication and transcription. Currently, there are no approved antivirals or vaccines for Andes Hantavirus or other Hantaviruses. About Cocrystal Pharma's Structure-Based Drug Discovery Platform Cocrystal is leveraging its structure‑based drug discovery platform technology to design next‑generation antiviral candidates that precisely target viral replication mechanisms.

Hantaviruses are primarily transmitted by rodents, although human-to-human transmission can occur through prolonged close contact. Andes Hantavirus, a member of the genus Hantavirus, is endemic in Argentina and Chile and causes Hantavirus cardiopulmonary syndrome (HCPS), which is associated with a case fatality rate of up to 50%. By binding to highly conserved regions of viral enzymes, the Company's compounds aim to maintain potency against mutating strains while minimizing off‑target effects, offering potentially safer, broad‑spectrum antiviral solutions.

The goal of this technology is to facilitate the development of novel broad-spectrum antivirals for the treatment of acute, chronic and potentially pandemic viral diseases. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create viable antiviral drugs. This approach streamlines candidate identification and optimization, enabling more rapid progression of promising therapies with robust resistance and safety profiles.